“Discovery of TNG462: A Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitor to Target Cancers with MTAP Deletion” was recently published in the Journal of Medicinal Chemistry. TNG462 is a potent and selective MTA-cooperative PRMT5 inhibitor with favorable drug metabolism and pharmacokinetic properties. TNG462 as a single agent is currently under investigation in patients with NSCLC, mesothelioma, pancreatic cancer, and other solid non-CNS tumors in the Phase I/II clinical trial (NCT05732831). Read the full manuscript on Journal of Medicinal Chemistry here:
Tango Therapeutics
Biotechnology Research
Boston, Massachusetts 17,433 followers
Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medicines.
About us
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
- Website
-
https://www.tangotx.com/
External link for Tango Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, Massachusetts
- Type
- Public Company
- Founded
- 2017
- Specialties
- cancer, pharmaceutical research, functional genomics, drug discovery, and synthetic lethality
Locations
-
Primary
201 Brookline Ave
Suite 901
Boston, Massachusetts 02215, US
Employees at Tango Therapeutics
Updates
-
Join us this afternoon as Barbara Weber, M.D., President and CEO, participates in a fireside chat at the Leerink Global Healthcare Conference. Learn more: https://lnkd.in/eMGwe8_V
-
-
As six associates and two family members “sprint to the marathon” in support of the Boston Celtics Shamrock Foundation, this week we’re profiling Jacob McAllister, Staff Accountant, Finance. At Tango, Jacob actively participates in the accounting close process, finance operations as well as supports SEC compliance. Outside of his day job, Jacob is busy training for the Boston Marathon on behalf of the Shamrock Foundation which provides grassroots programming and strategic funding to local organizations serving at risk or at need youth populations. If you’d like to support Jacob and his cause, please donate here: https://lnkd.in/e58RGbwU
-
-
International Women’s Day provides an opportunity to recognize the more than 90 remarkable women of Tango – who make up more than half of the company – and the myriad ways they contribute to our leadership, culture and science: 👩⚕️ More than a third are managers or in leadership positions – including our CEO Barbara Weber, MD, CFO Daniella Beckman, Chief Development Operations Officer Heather DiBenedetto, Chief Human Resources Officer Julie Carretero and SVP, Head of Clinical Development Maeve Waldron-Lynch. 🔊 21 speak more than one language including Mandarin, French, Spanish and Marathi 🌎 They are global and diverse. 31 were born outside of the U.S. and 13 have worked in other countries including Thailand, Finland, Austria, Kenya and India as researchers, while enrolled in school, or as working professionals 🏫 More than half hold advanced degrees including two M.D.’s, 14 Ph.D.’s, two J.D.’s, two PharmD’s and 27 master’s degrees Each plays a critical role in advancing our mission to develop the next generation of precision cancer treatments. Thank you all for your contributions! #IWD2025
-
-
As six associates and two family members “sprint to the marathon” in support of the Boston Celtics Shamrock Foundation, this week we’re profiling Jerrod Zimmer, Senior Analyst, Financial Planning & Analysis. At Tango, Jerrod partners with departments across the company to build budgets and analyze the company's financial data to provide insights for strategic decision making. Outside of his day job, Jerrod is busy training for the Boston Marathon on behalf of the Shamrock Foundation which provides grassroots programming and strategic funding to local organizations serving at risk or at need youth populations. If you’d like to support Jerrod and his cause, please donate here: https://lnkd.in/e5ncGzuW
-
-
“Development of a Commercial Ready Process for TNG908: A Potent, Selective, and Brain-Penetrant MTA-Cooperative PRMT5 Inhibitor” was recently published in Organic Process Research & Development. The article describes the chemical process development for TNG908, an MTA-cooperative PRMT5 inhibitor that we have since stopped further development. Improvements were made to the original process in order to produce active pharmaceutical ingredient (API) with higher yields and better purity, resulting in a convergent, diastereoselective, safe, reproducible and robust commercial ready process. Read the full article in Organic Process Research & Development:
-
$TNGX news: Today we announced Q4 and full year 2024 financial results and recent business highlights, including: TNG462 granted Orphan Drug Designation (ODD) for treatment of pancreatic cancer, Investigational New Drug (IND) application for TNG456 cleared by the U.S. Food and Drug Administration (FDA) and a clinical collaboration established with Eli Lilly to evaluate TNG456 in combination with CDK4/6 inhibitor Verzenio (abemaciclib). Read the full announcement here: https://lnkd.in/e4x9Sc-6
-
-
As six associates and two family members “sprint to the marathon” in support of the Boston Celtics Shamrock Foundation, this week we’re profiling Gina Calvanese, Manager, Administration. At Tango, Gina supports our President and CEO and manages an admin team of seven. Outside of her day job, Gina is busy training for the Boston Marathon on behalf of the Shamrock Foundation which provides grassroots programming and strategic funding to local organizations serving at risk or at need youth populations. If you’d like to support Gina and her cause, please donate here: https://lnkd.in/eCf3hvwS
-
-
Happy Lunar New Year! At Tango, we celebrated with Asian-inspired food and drinks, cultural activities such as water coloring and mahjong and watched a traditional dragon dance performance and presentation by Sirimas Sudsakorn about the meaning of Lunar New Year and how her family celebrates. We hope the Year of the Snake provides you with wisdom, transformation, calmness and renewal!
-
"MTA-Cooperative PRMT5 Inhibitors: Mechanism Switching Through Structure-Based Design” was recently published in the Journal of Medicinal Chemistry. This article describes the discovery of novel compounds using structure-based design to switch the mechanism of binding of known SAM-cooperative PRMT5 inhibitors to an MTA-cooperative binding mechanism, allowing them to selectively target MTAP-deleted cancer cells. These compounds have proven to be important tools for the advancement of our understanding of the biology in the MTA-cooperative PRMT5 space. Read the full article in the Journal of Medicinal Chemistry: